Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:mucormycosis
|
| gptkbp:activities |
gptkb:Zygomycetes
gptkb:Aspergillus_species gptkb:Candida_species gptkb:Cryptococcus_neoformans Fusarium species inhibits ergosterol synthesis |
| gptkbp:approves |
gptkb:2006
gptkb:FDA |
| gptkbp:brand |
Noxafil
|
| gptkbp:category |
Category C
not recommended |
| gptkbp:clinical_trial |
Phase III
immunocompromised patients patients undergoing stem cell transplant patients with hematological malignancies patients with solid organ transplants |
| gptkbp:contraindication |
concurrent use of certain medications
hypersensitivity to posaconazole |
| gptkbp:developed_by |
gptkb:Schering-Plough
|
| gptkbp:formulation |
gptkb:tablet
suspension injectable solution |
| https://www.w3.org/2000/01/rdf-schema#label |
posaconazole
|
| gptkbp:indication |
prophylaxis of invasive fungal infections
|
| gptkbp:ingredients |
C17 H19 F2 N3 O
|
| gptkbp:interacts_with |
gptkb:warfarin
statins CY P3 A4 inducers CY P3 A4 inhibitors |
| gptkbp:is_atype_of |
J02 A C04
|
| gptkbp:is_used_for |
treatment of fungal infections
|
| gptkbp:manager |
oral
intravenous |
| gptkbp:marketed_as |
gptkb:legislation
gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:pharmacokinetics |
highly protein-bound
metabolized by liver excreted in feces fungistatic activity |
| gptkbp:research_areas |
combination therapy
new formulations antifungal resistance |
| gptkbp:side_effect |
headache
nausea abdominal pain diarrhea liver toxicity QT prolongation |
| gptkbp:type_of |
171228-49-2
|